CD274 and adenocarcinoma: The use of pembrolizumab with platinum + paclitaxel ± bevacizumab is recommended for patients with metastatic, recurrent, or persistent CC with PD-L1 CPS ≥1%, of squamous, adenocarcinoma, or adenosquamous histology, as first-line treatment.